Cancer and Parkinson's disease: The odd couple

Drugs of Today

Volumn 47, Issue 3, 2011, Pages 215-222

  Gao, Xiang ^a,b   Ning, Y ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DJ 1 PROTEIN; LEUCINE RICH REPEAT KINASE 2; LEVODOPA;

BREAST CANCER; CANCER RISK; COLORECTAL CANCER; COMORBIDITY; DISEASE COURSE; ENVIRONMENTAL FACTOR; FOLLOW UP; HEREDITY; HUMAN; LEUKEMIA; LIFESTYLE; LUNG CANCER; LYMPHOMA; MELANOMA; NEOPLASM; PARKINSON DISEASE; PATHOGENESIS; PROSTATE CANCER; REVIEW; SMOKING; SOCIAL STATUS; GENETICS; SOCIAL CLASS;

HUMANS; LEVODOPA; LIFE STYLE; MELANOMA; NEOPLASMS; PARKINSON DISEASE; SMOKING; SOCIAL CLASS;

EID: 80051938181     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2011.47.3.1519657     Document Type: Review

References (77)

1. Lang, A.E., Lozano, A.M. Parkinson's disease. First of two parts. N Engl J Med 1998, 339(15): 1044-53.
2. Bajaj, A., Driver, J.A., Schernhammer, E.S. Parkinson's disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control 2010, 21(5): 697-707.
3. Olsen, J.H., Friis, S., Frederiksen, K. Malignant melanoma and other types of cancer preceding Parkinson disease. Epidemiology 2006, 17(5): 582-7.
4. Olsen, J.H., Friis, S., Frederiksen, K., McLaughlin, J.K., Mellemkjaer, L., Moller, H. Atypical cancer pattern in patients with Parkinson's disease. Br J Cancer 2005, 92(1):201-5.
5. Skibba, J.L., Pinckley, J., Gilbert, E.F., Johnson, R.O. Multiple primary melanoma following administration of levodopa. Arch Pathol 1972, 93(6): 556-61.
6. Fiala, K.H., Whetteckey, J., Manyam, B.V. Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence? Parkinsonism Relat Disord 2003, 9(6): 321-7.
7. Pfutzner, W., Przybilla, B. Malignant melanoma and levodopa: is there a relationship? Two new cases and a review of the literature. J Am Acad Dermatol 1997, 37(2 Pt 2): 332-6.
8. Siple, J.F., Schneider, D.C., Wanlass, W.A., Rosenblatt, B.K. Levodopa therapy and the risk of malignant melanoma. Ann Pharmacother 2000, 34(3): 382-5.
9. Becker, C., Brobert, G.P., Johansson, S., Jick, S.S., Meier, C.R. Cancer risk in association with Parkinson disease: a population-based study. Parkinsonism Relat Disord 2010, 16(3): 186-90.
10. Driver, J.A., Kurth, T., Buring, J.E., Gaziano, J.M., Logroscino, G. Prospective case-control study of nonfatal cancer preceding the diagnosis of Parkinson's disease. Cancer Causes Control 2007, 18(7): 705-11.
11. Fois, A.F., Wotton, C.J., Yeates, D., Turner, M.R., Goldacre, M.J. Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson's disease: record linkage studies. J Neurol Neurosurg Psychiatry 2010, 81(2): 215-21.
12. Driver, J.A., Logroscino, G., Buring, J.E., Gaziano, J.M., Kurth, T. A prospective cohort study of cancer incidence following the diagnosis of Parkinson's disease. Cancer Epidemiol Biomarkers Prev 2007, 16(6): 1260-5.
13. Elbaz, A., Peterson, B.J., Yang, P. et al. Nonfatal cancer preceding Parkinson's disease: a case-control study. Epidemiology 2002, 13(2): 157-64.
14. Gandini, S., Botteri, E., Iodice, S., Boniol, M., Lowenfels, A.B., Maisonneuve, P., Boyle, P. Tobacco smoking and cancer: a meta-analysis. Int J Cancer 2008, 122(1): 155-64.
15. Botteri, E., Iodice, S., Bagnardi, V., Raimondi, S., Lowenfels, A.B., Maisonneuve, P. Smoking and colorectal cancer: a meta-analysis. JAMA 2008, 300(23): 2765-78.
16. Hernan, M.A., Takkouche, B., Caamano-Isorna, F., Gestal-Otero, J.J. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 2002, 52(3): 276-84.
17. Ritz, B., Ascherio, A., Checkoway, H. et al. Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol 2007, 64(7): 990-7.
18. Thacker, E.L., O'Reilly, E.J., Weisskopf, M.G. et al. Temporal relationship between cigarette smoking and risk of Parkinson disease. Neurology 2007, 68(10): 764-8.
19. O'Reilly, E.J., Chen, H., Gardener, H., Gao, X., Schwarzschild, M.A., Ascherio, A. Smoking and Parkinson's disease: Using parental smoking as a proxy to explore causality. Am J Epidemiol 2009, 169(6): 678-82.
20. Jansson, B., Jankovic, J. Low cancer rates among patients with Parkinson's disease. Ann Neurol 1985, 17(5): 505-9.
21. Brehm, J.M., Celedon, J.C., Soto-Quiros, M.E. et al. Serum vitamin D levels and markers of severity of childhood asthma in Costa Rica. Am J Respir Crit Care Med 2009, 179(9): 765-71.
22. Forman, J.P., Giovannucci, E., Holmes, M.D., Bischoff-Ferrari, H.A., Tworoger, S.S., Willett, W.C., Curhan, G.C. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 2007, 49(5): 1063-9.
23. Chen, H., Zhang, S.M., Hernan, M.A., Willett, W.C., Ascherio, A. Weight loss in Parkinson's disease. Ann Neurol 2003, 53(5): 676-9.
24. Durrieu, G., ME, L.L., Rascol, O., Senard, J.M., Rascol, A., Montastruc, J.L. Parkinson's disease and weight loss: a study with anthropometric and nutritional assessment. Clin Auton Res 1992, 2(3): 153-7.
25. Minami, Y., Ohuchi, N., Taeda, Y., Takano, A., Fukao, A., Satomi, S., Hisamichi, S. Risk of breast cancer in Japanese women with benign breast disease. Jpn J Cancer Res 1999, 90(6): 600-6.
26. D'Amelio, M., Ragonese, P., Morgante, L., Reggio, A., Callari, G., Salemi, G., Savettieri, G. Long-term survival of Parkinson's disease: a population-based study. J Neurol 2006, 253(1): 33-7.
27. Moller, H., Mellemkjaer, L., McLaughlin, J.K., Olsen, J.H. Occurrence of different cancers in patients with Parkinson's disease. BMJ 1995, 310(6993): 1500-1.
28. Olanow, C.W., McNaught, K.S. Ubiquitin-proteasome system and Parkinson's disease. Mov Disord 2006, 21(11): 1806-23.
29. Lim, K.L., Tan, J.M. Role of the ubiquitin proteasome system in Parkinson's disease. BMC Biochem 2007, 8(Suppl. 1): S13.
30. Cook, C., Petrucelli, L. A critical evaluation of the ubiquitinproteasome system in Parkinson's disease. Biochim Biophys Acta 2009, 1792(7): 664-75.
31. Sterz, J., von Metzler, I., Hahne, J.C. et al. The potential of proteasome inhibitors in cancer therapy. Expert Opin Investig Drugs 2008, 17(6): 879-95.
32. Testa, U. Proteasome inhibitors in cancer therapy. Curr Drug Targets 2009, 10(10): 968-81.
33. Zhou, W., Freed, C.R. DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T alpha-synuclein toxicity. J Biol Chem 2005, 280(52): 43150-8.
34. Shendelman, S., Jonason, A., Martinat, C., Leete, T., Abeliovich, A. DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. PLoS Biol 2004, 2(11): e362.
35. Moore, D.J., Dawson, V.L., Dawson, T.M. Role for the ubiquitin-proteasome system in Parkinson's disease and other neurodegenerative brain amyloidoses. Neuromolecular Med 2003, 4(1-2): 95-108.
36. Le Naour, F., Misek, D.E., Krause, M.C., Deneux, L., Giordano, T.J., Scholl, S., Hanash, S.M. Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin Cancer Res 2001, 7(11): 3328-35.
37. Arnouk, H., Merkley, M.A., Podolsky, R.H. et al. Characterization of molecular markers indicative of cervical cancer progression. Proteomics Clin Appl 2009, 3(5): 516-27.
38. MacKeigan, J.P., Clements, C.M., Lich, J.D., Pope, R.M., Hod, Y., Ting, J.P. Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: identification of RS/DJ-1 and RhoGDIalpha. Cancer Res 2003, 63(20): 6928-34.
39. Ren, H., Fu, K., Mu, C., Li, B., Wang, D., Wang, G. DJ-1, a cancer and Parkinson's disease associated protein, regulates autophagy through JNK pathway in cancer cells. Cancer Lett 2010, 297(1): 101-8.
40. Morris, L.G., Veeriah, S., Chan, T.A. Genetic determinants at the interface of cancer and neurodegenerative disease. Oncogene 2010, 29(24): 3453-64.
41. Veeriah, S., Taylor, B.S., Meng, S. et al. Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet 2010, 42(1): 77-82.
42. Kim, H.J., Kim, Y.M., Lim, S., Nam, Y.K., Jeong, J., Kim, H.J., Lee, K.J. Ubiquitin C-terminal hydrolase-L1 is a key regulator of tumor cell invasion and metastasis. Oncogene 2009, 28(1): 117-27.
43. Okochi-Takada, E., Nakazawa, K., Wakabayashi, M., Mori, A., Ichimura, S., Yasugi, T., Ushijima, T. Silencing of the UCHL1 gene in human colorectal and ovarian cancers. Int J Cancer 2006, 119(6): 1338-44.
44. Deas, E., Plun-Favreau, H., Wood, N.W. PINK1 function in health and disease. EMBO Mol Med 2009, 1(3): 152-65.
45. Constantinescu, R., Romer, M., Kieburtz, K. Malignant melanoma in early Parkinson's disease: the DATATOP trial. Mov Disord 2007, 22(5): 720-2.
46. Bertoni, J.M., Arlette, J.P., Fernandez, H.H. et al. Increased melanoma risk in Parkinson disease: a prospective clinicopathological study. Arch Neurol 2010, 67(3): 347-52.
47. Schwid, S.R., Bausch, J., Oakes, D. et al. Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease. Mov Disord 2010, 25(12): 1801-8.
48. Lo, R.Y., Tanner, C.M., Van Den Eeden, S.K., Albers, K.B., Leimpeter, A.D., Nelson, L.M. Comorbid cancer in Parkinson's disease. Mov Disord 2010, 25(12): 1809-17.
49. Fois, A.F., Wotton, C.J., Yeates, D., Turner, M.R., Goldacre, M.J. Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson's disease: record linkage studies. J Neurol Neurosurg Psychiatry 2010, 81(2): 215-21.
50. Powers, K.M., Smith-Weller, T., Franklin, G.M., Longstreth, W.T., Jr., Swanson, P.D., Checkoway, H. Diabetes, smoking, and other medical conditions in relation to Parkinson's disease risk. Parkinsonism Relat Disord 2006, 12(3): 185-9.
51. Olsen, J.H., Tangerud, K., Wermuth, L., Frederiksen, K., Friis, S. Treatment with levodopa and risk for malignant melanoma. Mov Disord 2007, 22(9): 1252-7.
52. Charles, J., Templier, I., Leroux, D., Salameire, D., Robert, C., Lantuejoul, S., Leccia, M.T. Twenty-two cutaneous primary melanomas in a patient with high genetic predisposition to melanoma receiving levodopa therapy for Park-inson's disease. Pigment Cell Melanoma Res 2009, 22(6): 851-3.
53. Grant, W.B. Smoking, Parkinson's disease, and melanoma. Cancer Epidemiol Biomarkers Prev 2007, 16(11): 2517-8.
54. Wirdefeldt, K., Gatz, M., Pawitan, Y., Pedersen, N.L. Risk and protective factors for Parkinson's disease: a study in Swedish twins. Ann Neurol 2005, 57(1): 27-33.
55. Freedman, D.M., Sigurdson, A., Doody, M.M., Rao, R.S., Linet, M.S. Risk of melanoma in relation to smoking, alcohol intake, and other factors in a large occupational cohort. Cancer Causes Control 2003, 14(9): 847-57.
56. Odenbro, A., Gillgren, P., Bellocco, R., Boffetta, P., Hakansson, N., Adami, J. The risk for cutaneous malignant melanoma, melanoma in situ and intraocular malignant melanoma in relation to tobacco use and body mass index. Br J Dermatol 2007, 156(1): 99-105.
57. Birch-Johansen, F., Hvilsom, G., Kjaer, T., Storm, H. Social inequality and incidence of and survival from malignant melanoma in a population-based study in Denmark, 1994-2003. Eur J Cancer 2008, 44(14): 2043-9.
58. Shack, L., Jordan, C., Thomson, C.S., Mak, V., Moller, H. Variation in incidence of breast, lung and cervical cancer and malignant melanoma of skin by socioeconomic group in England. BMC Cancer 2008, 8(1): 271.
59. Grant, W.B. Skin aging from ultraviolet irradiance and smoking reduces risk of melanoma: epidemiological evidence. Anticancer Res 2008, 28(6B): 4003-8.
60. Gao, X., Simon, K.C., Han, J., Schwarzschild, M.A., Ascherio, A. Genetic determinants of hair color and Parkinson's disease risk. Ann Neurol 2009, 65(1): 76-82.
61. Zanetti, R., Rosso, S. Levodopa and the risk of melanoma. Lancet 2007, 369(9558): 257-8.
62. Herrero Hernandez, E. Pigmentation genes link Parkinson's disease to melanoma, opening a window on both etiologies. Med Hypotheses 2009, 72(3): 280-4.
63. Gao, X., Simon, K.C., Han, J., Schwarzschild, M.A., Ascherio, A. Family history of melanoma and Parkinson disease risk. Neurology 2009, 73(16): 1286-91.
64. Han, J., Kraft, P., Colditz, G.A., Wong, J., Hunter, D.J. Melanocortin 1 receptor variants and skin cancer risk. Int J Cancer 2006, 119(8): 1976-84.
65. Palmer, J.S., Duffy, D.L., Box, N.F. et al. Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet 2000, 66(1): 176-86.
66. Kennedy, C., ter Huurne, J., Berkhout, M. et al. Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol 2001, 117(2): 294-300.
67. Landi, M.T., Kanetsky, P.A., Tsang, S. et al. MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population. J Natl Cancer Inst 2005, 97(13): 998-1007.
68. Matichard, E., Verpillat, P., Meziani, R. et al. Melanocortin 1 receptor (MC1R) gene variants may increase the risk of melanoma in France independently of clinical risk factors and UV exposure. J Med Genet 2004, 41(2): e13.
69. Box, N.F., Duffy, D.L., Irving, R.E. et al. Melanocortin-1 receptor genotype is a risk factor for basal and squamous cell carcinoma. J Invest Dermatol 2001, 116(2): 224-9.
70. Dwyer, T., Stankovich, J.M., Blizzard, L. et al. Does the addition of information on genotype improve prediction of the risk of melanoma and nonmelanoma skin cancer beyond that obtained from skin phenotype? Am J Epidemiol 2004, 159(9): 826-33.
71. van der Velden, P.A., Sandkuijl, L.A., Bergman, W., Pavel, S., van Mourik, L., Frants, R.R., Gruis, N.A. Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma. Am J Hum Genet 2001, 69(4): 774-9.
72. Tanner, C.M., Nelson, L.M., Van Den Eeden, S.K., Harrington, E.P., Bernstein, A.L. Skin pigmentation and risk of Parkinson's disease (abstract). Neurology 1999, 52(Suppl. 2): 540.
73. Funayama, M., Hasegawa, K., Kowa, H., Saito, M., Tsuji, S., Obata, F. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 2002, 51(3): 296-301.
74. Orr-Urtreger, A., Shifrin, C., Rozovski, U. et al. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect? Neurology 2007, 69(16): 1595-602.
75. Thaler, A., Ash, E., Gan-Or, Z., Orr-Urtreger, A., Giladi, N. The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews. J Neural Transm 2009, 116(11): 1473-82.
76. Hassin-Baer, S., Laitman, Y., Azizi, E. et al. The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation. Association with Parkinson disease, malignant melanoma and prevalence in ethnic groups in Israel. J Neurol 2009, 256(3): 483-7.
77. Matsuo, Y., Kamitani, T. Parkinson's disease-related protein, alpha-synuclein, in malignant melanoma. PLoS One 2010, 5(5): e10481.